Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo

Trial Profile

Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo

Recruiting
Phase of Trial: Phase III

Latest Information Update: 25 May 2017

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Haemolytic uraemic syndrome
  • Focus Therapeutic Use
  • Acronyms ECULISHU
  • Most Recent Events

    • 02 Oct 2015 Post-hoc analysis data will be presented at the 2015 American Society of Nephrology (ASN) Annual Meeting, as per Alexion media release.
    • 25 Aug 2015 Planned End Date changed from 1 Aug 2017 to 1 Jun 2018, as reported by ClinicalTrials.gov.
    • 25 Aug 2015 Planned primary completion date changed from 1 Aug 2017 to 1 Jun 2018, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top